MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry
NCT ID: NCT01347944
Last Updated: 2019-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
149 participants
OBSERVATIONAL
2011-01-01
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality
NCT00874978
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
NCT02279654
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
NCT01243476
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
NCT01029262
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
NCT04036448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lenalidomide
Patients who were prescribed Revlimid from 31October 2008 to present.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. transfusion dependency anemia (at least 2 units per 8 weeks before starting of Revlimid treatment )
2. 5q31-33 deletion isolated or associated to other chromosomal abnormalities.
Exclusion Criteria
* child bearing potential females who do not use adequate contraceptive methods
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sante Cundari, PhD, MSc
Role: STUDY_DIRECTOR
Celgene s.r.l.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dipartimento Onco - Ematologico Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo
Alessandria, , Italy
Unità Operativa Clinica di Ematologia Azianda Ospedaliero Universitaria Ospedali Riuniti di Ancona
Ancona, , Italy
Dipartimento di Oncologia Medica Ospedale Cardinale G. Massaia
Asti, , Italy
Ematologia Azienda Ospedaliera Universitaria Policlinico di Bari
Bari, , Italy
Dipartimento di Ematologia Ospedale dell'U.L.S.S. n.1 Belluno
Belluno, , Italy
Ematologia A.O. Ospedale Riuniti di Bergamo
Bergamo, , Italy
Dip. Medicina Interna Ospedale degli Infermi di Biella
Biella, , Italy
Dipartimento di Ematologia Spedale Civili di Brescia
Brescia, , Italy
Dipartimento Trapianto di Midollo Allogenico Spedale Civili di Brescia
Brescia, , Italy
Dipartimento di Ematologia Ospedale R. Binaghi
Cagliari, , Italy
Dip. Di Oncoematologia A.O. S.Anna e S. Sebastiano
Caserta, , Italy
Dip. Di Ematologia A.O. Istituti Ospedalieri
Cremona, , Italy
Dip. Di Ematologia Az. Ospedaliero-Universitaria Careggi
Florence, , Italy
Dip. Di Ematologia A.O. Universitaria S. Martino
Genova, , Italy
Dip. Di Medicina Interna A.O. Universitaria S. Martino
Genova, , Italy
Dip. Di Ematologia Azienda Ospedaliera V. Fazzi
Lecce, , Italy
Centro Trapianti di Midollo Ospedale Maggiore Policlinico
Milan, , Italy
Dip. Di Ematologia Policlinico, Az. Ospedaliero- Universitaria
Modena, , Italy
Dip. Di Ematologia Azienda Ospedaliera S. Gerardo
Monza, , Italy
Dip. Di Oncoematologia A.O. Universitaria Federico II
Napoli, , Italy
Dip. Di Ematologia Presidio Ospedaliero Umberto I
Nocera Inferiore, , Italy
Dip. Di Ematologia Ospedale S. Francesco
Nuoro, , Italy
Dip. Di Ematologia Azienda Ospedaliera
Padua, , Italy
Dip. di Ematologia Azienda Ospedaliera
Parma, , Italy
Dip. Di Ematologia Azienda Ospedaliera - Osp. S. Maria della Misericordia
Perugia, , Italy
Dip. Di Ematologia Azienda Ospedaliera s. Salvatore
Pesaro, , Italy
Dip. Di Ematologia Az. Ospedaliera Regionale S. Carlo
Potenza, , Italy
Servizio di Ematologia - Dip. di Oncologia Az. Ospedaliera di Reggio Emilia - Arcispedale S. Maria Nuova
Reggio Emilia, , Italy
Dip. Di Ematologia Ospedale S. Maria delle Croci
Revenna, , Italy
U. O. Ematologia Az. Ospedaliero-Universitaria Policlinico Tor Vergata
Roma, , Italy
U.O.C Ematologia Ospedale S. Eugenio, Piazzale dell'Umanesimo
Roma, , Italy
Dip. di Ematologia Policlinico Umberto I
Roma, , Italy
U.O.C. Ematologia Policlinico Universitario Gemelli
Roma, , Italy
Dip. di Oncoematologia Ospedale Civile Giannettasio
Rossano, , Italy
Dip. di Oncoematologia Az. ULSS 18
Rovigo, , Italy
Struttura di Ematologia, Dip. di Oncoematologia IRCCS Casa Sollievo della Sofferenza
San Giovanni Rotondo, , Italy
Dip. di Ematologia Policlinico Universitario di Sassari
Sassari, , Italy
Divisione di Ematologia e Trapianti Spedali Riuniti
Siena, , Italy
Dip. di Ematologia 1 A.O. Universitaria S.Giovanni Battista
Torino, , Italy
Dip. di Ematologia 2 A.O. Universitaria S.Giovanni Battista
Torino, , Italy
Dip. di Ematologia e Terapie Cellulari Ospedale Mauriziano Umberto I
Torino, , Italy
Unità Operativa Trasfusionale ed Immunologia Centro di riferimento per le malattie rare e centro regionale per le malattie del sangue Ospedale S. Giacomo Apostolo
Treviso, , Italy
Ospedale Dell'Angelo USL12 - Venezia (Mestre)
Venezia, , Italy
Dip. Funzionale di Terapie Cellulari e Ematologia Azienda Sanitaria ULSS 6 - Osp. di Vicenza
Vicenza, , Italy
Dip. Di Ematologia Ospedale di Belcolle
Viterbo, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C; MORE Study Centres. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. Eur J Haematol. 2018 Jul;101(1):78-85. doi: 10.1111/ejh.13067. Epub 2018 May 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIPMS- Celgene-MDS-ITA-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.